E596 - elosulfase alfa [1 mg/ML 5 ML sol inj f/amp]

This tender, identified as E596, is for the procurement of Elosulfate Alfa, specifically presented as a 1 mg/ml solution for injection in 5 ml vials. The contracting authority, managed by the Publications Office of the European Union, is seeking to acquire this pharmaceutical product for distribution and use within Portugal.

Elosulfate Alfa is a therapeutic agent, and this procurement likely falls under the category of medical supplies or specialized pharmaceuticals. The tender will require suppliers to demonstrate their capability to provide a high-quality, sterile injectable solution. Typical requirements for such tenders include adherence to stringent Good Manufacturing Practices (GMP) and relevant pharmaceutical regulatory standards. Bidders will need to provide detailed product specifications, including information on active pharmaceutical ingredient (API) sourcing, manufacturing processes, quality control measures, and shelf-life. Furthermore, evidence of regulatory approval from relevant authorities, such as the European Medicines Agency (EMA) or national competent authorities, will be essential. Packaging and labeling must comply with European Union directives and Portuguese national regulations. Consideration will also be given to the supplier's logistical capabilities to ensure secure and timely delivery of the product to designated locations within Portugal, maintaining the required temperature and handling conditions throughout the supply chain.